BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of “Moderate Buy” by Brokerages

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twenty-four analysts that are currently covering the stock, reports. Nine analysts have rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year target price among analysts […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set Planet Fitness, Inc. (NYSE:PLNT) PT at $69.18
Next post Spectris plc (LON:SXS) Given Consensus Recommendation of “Moderate Buy” by Brokerages